ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1371	National Cancer Institute	Html	en	Testicular Cancer Screening (PDQ®)–Health Professional Version	For testicular cancer, there is no standard or routine screening test. Review the limited evidence on the benefits and harms of screening for testicular cancer using ultrasound, physical examination, and self-examination in this expert-reviewed summary.	positive predictive value 0.695776 routine screening 0.564923 metastatic potential 0.563198 Anaplastic seminoma accounts 0.622576 different geographical areas 0.620061 physical examination 0.605096 clinical testicular examination 0.721514 Caucasian populations. 0.566499 testicular cancer 0.951907 postnatal risk factor 0.601402 white men 0.624527 ethnic groups 0.563052 testicular cancers 0.797374 previously impalpable gonad 0.603117 effective treatments 0.565355 intermediate incidence rates 0.604976 American population. 0.564647 annual increase 0.563525 dramatic decrease 0.576242 observed incidence 0.56787 new cases 0.568142 appreciable change 0.564646 testicular self-examination 0.687127 genetic risk factors 0.600847	single-center case series 0.602561 U.S. Preventive Services 0.59719 United States 0.618395 testicular tumors 0.686049 pure seminomas 0.561939 testicular symptoms 0.684314 common cancer 0.580765 common malignancy 0.57065 quasi-randomized controlled trials 0.594715 Cochrane Collaboration review 0.593748 asymptomatic population. 0.565357 routine physical examination 0.599315 black men 0.575106 Classic seminoma accounts 0.61307 Testicular Cancer Treatment 0.746488 United Kingdom 0.56682 young men 0.581551 higher rate 0.65969 human chorionic gonadotropin 0.610455 asymptomatic men 0.627381 testicular ultrasound. 0.684097 mortality 0.565405 greater mitotic activity 0.608461 screening setting 0.564489	CLICK HERE
1505	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	high response rates 0.570253 significant advantage 0.396071 segmental excision 0.901561 distal ureter 0.436419 lymph node dissection 0.603868 single-agent cisplatin 0.443409 transitional cell carcinoma 0.586392 renal pelvic tumors 0.538563 overall response rate 0.528335 pelvic transitional cell 0.448218 upper tract unit 0.412776 Flow cytometry analysis 0.411659 renal pelvic neoplasia 0.501661 ipsilateral ureter 0.431511 bladder cuff 0.478483 tumor grade 0.387333 ureter 0.507683 decreased renal function 0.469412 randomized trial 0.409787 advanced bladder cancer 0.608478 cooperative group trial 0.54025 M-VAC 0.376891 probable extensive involvement 0.400061 low-grade lesions 0.376767 incomplete excision 0.438555	transitional cell cancer 0.423006 occasional complete responses. 0.574974 median survival 0.546148 flexible ureteroscopic techniques 0.426625 low-grade tumors 0.414223 total excision 0.42951 unique structural aspects 0.436892 proximal disease 0.421433 tumor recurrence 0.752566 entire ureter 0.43284 regional lymph node 0.419107 upper tract tumors 0.459629 subepithelial connective tissue 0.406583 recurrent transitional cell 0.585792 combination chemotherapy 0.403167 highly selected patients 0.420394 original pelvic tumor 0.49757 lymph node involvement 0.412201 section histologic diagnosis 0.406599 periureteral orifice mucosa 0.421167 upper tract 0.553387 upper tract neoplasm 0.442928 renal pelvis 0.622775 transitional cell 0.664348	CLICK HERE
1563	National Cancer Institute	Html	en	Intraocular (Uveal) Melanoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of intraocular (uveal) melanoma.	intraocular melanoma spreads 0.250336 intraocular melanoma 0.910343 millimeters 0.391159 metastatic intraocular melanoma 0.214724 PDQ cancer information 0.259005 choroid 0.268515 clinical trial search 0.285225 cancer information summary 0.225998 clinical trial 0.443006 iris 0.239636 Gamma Knife therapy 0.228475 patients 0.209232 blood vessels 0.304976 intraocular melanoma tumors 0.226899 eye 0.424632 radiation therapy 0.510988 malignant tumor cells 0.271535 optic nerve 0.24596 eyeball 0.243675 intraocular melanoma forms 0.241987 small choroid melanoma 0.211146 treatment 0.429108 Charged-particle external-beam radiation 0.231587 intraocular melanoma cells 0.228349 recurrent intraocular melanoma 0.212624	choroid melanoma 0.222278 NCI-supported cancer 0.212728 cancer cells 0.209946 plaque radiation therapy 0.308242 small tumor 0.233192 common eye cancer 0.210231 treatment clinical trials 0.228682 National Cancer Institute 0.24241 new treatment 0.231582 external-beam radiation therapy 0.278674 clinical trials 0.677613 primary tumor 0.231468 ciliary body 0.781488 metastatic tumor 0.244372 medium choroid melanoma 0.210302 large choroid melanoma 0.209378 cancer clinical trials 0.291937 stage 0.237259 tumor 0.76237 high-energy sound waves 0.239767 treatment options 0.227265 internal radiation therapy 0.245892 cancer 0.592755 information 0.28047	CLICK HERE
1668	National Cancer Institute	Html	en	Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood atypical teratoid/rhabdoid tumors	sporadic atypical teratoid/rhabdoid 0.35389 Advanced Solid Tumors 0.266343 germline mutations 0.346295 Brain Tumor Registry 0.34992 PDQ cancer information 0.28675 childhood brain tumor 0.395256 highly malignant tumor 0.338658 children 0.248192 Teratoid/Rhabdoid Tumor Registry 0.377339 epithelial membrane antigen 0.26533 Tumors Treatment Overview 0.317468 teratoid rhabdoid tumor 0.482755 CNS embryonal tumor 0.333819 childhood atypical teratoid 0.359626 cancer information summary 0.273796 World Health Organization 0.305191 AT/RT 0.337582 renal rhabdoid tumor 0.427367 term rhabdoid tumor 0.444598 non-CNS tumors 0.241796 extrarenal rhabdoid malignancies. 0.28465 malignant rhabdoid tumor 0.405902 common solid tumor 0.361944 radiation therapy 0.251981 candidate tumor suppressor 0.315221	atypical teratoid/rhabdoid tumors 0.837543 Cribriform neuroepithelial tumor 0.311275 Rhabdoid cells 0.24146 CNS tumors 0.263956 posterior fossa 0.268656 PUBMED Abstract 0.244289 germline alterations 0.247965 tumor suppressor gene 0.428299 primitive neuroectodermal tumor 0.317136 Tumor location 0.308144 Primary brain tumors 0.317725 Pediatr Hematol Oncol 0.369559 nervous system tumors 0.313542 adolescent cancer survivors 0.310424 brain tumor 0.438808 Germline INI1 mutation 0.247063 atypical teratoid/rhabdoid tumor 0.959627 PDQ summary 0.241675 atypical teratoid tumor 0.422531 recurrent solid tumors 0.264311 Nervous System Atypical 0.266779 tumor diagnosis 0.312232 pediatric brain tumor 0.327372 Biegel JA 0.277305	CLICK HERE
1731	National Cancer Institute	Html	en	Oral Contraceptives and Cancer Risk	A fact sheet about research on the association of oral contraceptive use (birth control pills) with risk of various cancers.	oral contraceptives 0.917263 hereditary ovarian cancer 0.383854 commonly prescribed type 0.33973 liver cancer risk 0.373941 estrogen-progestogen contraceptives 0.386723 benign liver tumors 0.371652 risk level 0.342841 increased risk 0.351993 time oral contraceptives 0.52153 ovarian cancer 0.597198 cervical cancers 0.357191 birth control pills 0.477503 cervical cancer 0.513015 female hormones 0.362642 hormonal factors 0.355222 widely used contraceptives 0.420798 slightly higher risk 0.352236 oral contraceptive formulations 0.41375 human papillomavirus 0.360793 endometrial cancer 0.391533 Cancer Epidemiology Biomarkers 0.379203 Cancer Clinical Study 0.356619 women 0.413442 study 0.369792 United States 0.339309	low progestin levels 0.339553 endometrial cancer risk 0.376136 oral contraceptive contains 0.427683 oral contraception 0.377158 breast cancers 0.339078 National Cancer Institute 0.35154 oral contraceptive. 0.39193 epithelial ovarian cancer 0.36885 female hormones estrogen 0.346135 ovarian cancer risk 0.5032 epidemiological studies 0.347746 cervical cancer risk 0.402371 higher risk 0.352753 hormonal contraceptives 0.40794 breast cancer risk 0.408785 protective effect increases 0.369195 Abstract 0.338219 breast cancer 0.500449 malignant liver tumors 0.371449 birth control pill 0.342382 cancer risk 0.531533 et al 0.421561 New England Journal 0.388183 cancer 0.613253	CLICK HERE
1784	National Cancer Institute	Html	es	Complicaciones orales de la quimioterapia y la radioterapia a la cabeza y el cuello (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de las complicaciones orales, como la mucositis y la disfunción de la glándula salival, que se presentan en pacientes de cáncer tratados con quimioterapia y radioterapia a la cabeza y el cuello.	Cancer Inst Monogr 0.239559 Schubert MM 0.377541 cuidado dental 0.263915 Oral complications 0.73133 oral involvement 0.311957 Hong CH 0.250225 Stem Cell Transplantation 0.260042 tóxicos orales agudos 0.296836 infecciones víricas tardías 0.240097 mucosa inmunidad 0.238568 oral cryotherapy 0.302117 Oral Care Study 0.325881 efectos tóxicos directos 0.264484 oral básica 0.298176 cell transplantation 0.36439 Epstein JB 0.250634 hematopoietic cell transplantation 0.356137 Oral Dis 0.304725 Oral Oncology 0.315424 patients treated with 0.256291 oral sistemática 0.403576 Pretreatment oral assessment 0.299848 cáncer causa efectos 0.235719 células madre 0.562689 oncología oral 0.303702	Cancer Quality 0.23962 Care Cancer 0.911761 Brennan MT 0.291094 Oral biofilms 0.300769 Johnson BS 0.249495 recuperación hematopoyética infecciones 0.23764 Oral Oncol 0.388386 EICH oral aguda 0.30451 quimioterapia mielosupresora 0.237026 Dowd FJ 0.255583 Pathol Oral Radiol 0.29984 Complicaciones Citas 0.24913 patients receiving 0.238033 Sonis ST 0.246364 Peterson DE 0.312811 Mosby Elsevier 0.254331 Surg Oral Med 0.300003 systematic review 0.853357 6th ed 0.252103 dental extractions 0.245651 Yagiela JA 0.254334 Oral Maxillofac Surg 0.292509 cuidado oral 0.503096 oral citotoxicidad 0.308917	CLICK HERE
1880	National Cancer Institute	Html	es	Tratamiento del osteosarcoma e histiocitoma fibroso maligno óseo (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del osteosarcoma/histiocitoma fibroso maligno óseo.	extraosseous osteosarcoma 0.278507 Cancer Res Clin 0.254374 neoadjuvant cooperative osteosarcoma 0.358725 Orthop Relat Res 0.284141 cooperative osteosarcoma study 0.829513 german-austrian-swiss osteosarcoma study 0.35683 treated with neoadjuvant 0.233828 osteosarcoma after 0.343245 german cooperative osteosarcoma 0.359475 Cancer Res 0.262493 Radiat Oncol Biol 0.22414 Delling G 0.216109 prognostic factor 0.261147 Ferrari S 0.223793 Res Clin Oncol 0.245253 Bone Joint Surg 0.218249 Children's Oncology Group 0.273207 Natl Cancer Inst 0.230083 osteogenic sarcoma 0.27919 osteosarcoma study 0.934201 neoadjuvant chemotherapy 0.393798 patients with 0.508039 patients with sarcoma 0.221174 to neoadjuvant chemotherapy 0.216616 adult patients with 0.217534	with neoadjuvant chemotherapy 0.275342 Longhi A 0.235836 bone tumors 0.220948 osteosarcoma after treatment 0.281068 Skin Cancer 0.215986 Pediatr Blood Cancer 0.257287 extremities treated with 0.216311 osteosarcoma study group 0.718583 study group protocols 0.222417 report from 0.244375 Nucl Med 0.231164 with poor prognosis 0.215443 Surg Oncol 0.266751 with adjuvant chemotherapy 0.223288 Osteosarcoma over 0.282528 extremity treated with 0.216299 Pediatr Hematol Oncol 0.285762 Clin Oncol 0.832414 operable osteosarcoma 0.283119 patients treated 0.236043 cooperative german-austrian-swiss osteosarcoma 0.35251 Oncol Biol Phys 0.224271 Bacci G 0.350792 Oncology Group 0.276126	CLICK HERE
2010	National Cancer Institute	Html	es	Grados de comprobación científica de los estudios de investigación sobre detección y prevención del cáncer (PDQ®)–Versión para profesionales de salud	Información acerca de cómo evaluar la solidez de los datos probatorios obtenidos en los estudios de investigación sobre detección y prevención del cáncer.	Woolf SH 0.300601 Helfand M 0.300564 sección datos 0.302661 Current methods 0.300631 importancia clínica 0.300524 Consejo editorial usa 0.301821 datos probatorios indirectos 0.302664 Prev Med 0.300645 beneficios opción 0.300848 National Cancer Institute 0.300824 medida estudios 0.300552 Preventive Services Task 0.303591 Instituto Nacional 0.30261	Visuals Online 0.300487 intervenciones invasoras 0.300666 Harris RP 0.300578 Physician Data Query 0.300891 Services Task Force 0.303562 datos probatoriosUn estudio 0.301838 posibles beneficios 0.30077 datos probatorios 0.994126 acuerdo vs 0.301691 participantes vs 0.301672 US Preventive Services 0.301 perjuicios opción 0.301319 mejores estudios 0.300602	CLICK HERE
3415	National Cancer Institute	Html	en	NCI and the Precision Medicine Initiative®	NCI's activities related to precision medicine focuses on new and expanded precision medicine clinical trials; mechanisms to overcome drug resistance to cancer treatments; and developing a shared digital repository of precision medicine trials data.	Cancer Master Protocol 0.614776 precision oncology 0.587102 clinical response data 0.576467 Human Cancer Models 0.613841 medicine clinical trials 0.84157 Enrichment Marker Identification 0.553367 pilot extramural drug 0.559375 genetically targeted therapies 0.561429 cancer therapy 0.603283 NCI Patient-Derived Models 0.701176 cancer cell line 0.595282 immunotherapy clinical trials 0.61741 additional data sets 0.566068 patients 0.627055 cancer patients 0.582113 Genomic Data Commons 0.5718 Adjuvant Lung Cancer 0.615432 NCI 0.886136 human cancer 0.6328 precision medicine 0.986526 NCI early-phase trials 0.710312 relevant preclinical data 0.574529 human cancer cell 0.605887 drug resistance 0.561963 detailed sequencing analyses 0.555402	new laboratory models 0.716729 precision medicine trials 0.644469 Molecular Profiling-Based Assignment 0.559435 cancer research community 0.606845 radiation therapy studies 0.56117 Pediatric MATCH 0.560552 molecularly characterized samples 0.553516 basic science research 0.557964 cancer genomic data 0.620842 Health Information Technology 0.575335 Pediatric MATCH trial 0.556198 information technology activities 0.552169 national cancer knowledge 0.623766 Genomics Application Programming 0.551737 precision medicine trial 0.626418 patient-derived tumor xenografts 0.568278 NCI-sponsored clinical trials 0.575743 Cancer Genomics Cloud 0.600078 deep immunological characterizations 0.554067 Cancer Genome Atlas 0.587186 first-of-its-kind Molecular Analysis 0.56172 canine immunotherapy models 0.585673 cancer 0.698472 Precision Medicine Initiative® 0.646721	CLICK HERE
3932	National Cancer Institute	Html	es	Aprenda a relajarse	Ejercicios de relajación y de visualización para ayudar a reducir el dolor y el estrés del cáncer y de su tratamiento.	pequeña almohada 0.868399	agradable sensación 0.763417	CLICK HERE